期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Cycloset治疗2型糖尿病的研究进展 被引量：5

下载PDF
导出
摘要 由于糖尿病的发病率日趋增多,糖尿病相关并发症引起的致残、致死率也受到人们的日益关注。
作者 石维 许宇静 洪侃
机构地区 南京医科大学附属无锡人民医院内分泌科
出处 《实用临床医药杂志》 CAS 2011年第13期144-146,共3页 Journal of Clinical Medicine in Practice
关键词 cycloset 溴隐亭 糖尿病 2型
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献13

  • 1Brooks A M, Thacker S M. Dapagliflozin for the treatment of type 2 diabetes [ J ]. Ann Pharmacother, 2009, 43 ( 7 ) : 1286.
  • 2Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking[J]. Sleep Med Rev, 2007, 11(2): 113.
  • 3Cineotta A. Hypothalamic role in the insulin resistance syn- drome//[M]. Hansen B, Shaffrir E. Reistance and insulin resistance syndrome. London :Taylor & Francis, 2002: 271.
  • 4Cineotta A H, Meier A H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects [J]. Diabetes Care, 1996, 19(6): 667.
  • 5Veroseienee. Cycloset Package Insert, 2009. FDA approved label. Available from: http://www, aeeessdata, fda. gov/ drugsatfda-docs/label/2009/O208661bl, pdf [ Last acce.ssed 23 September 2009 ].
  • 6Luo S, Ezrokhi M, Trubitsyna Y , et al. Intrahypothalamic circuitry regulating hypothalanlic fuel sensing to induce insulin sensitivity or insulin resistance [abstract] [] ]. Diabetologia, 2008, 51(Suppl l) :S59.
  • 7Luo S, Luo J, Meier AH, et al. Dopaminergic neurotoxin administration to the area of the suprachiasmatie nuclei in- duces insulin resistance [J ]. Neuroreport, 1997, 8 ( 16 ) : 3495.
  • 8Cincotta AH, Luo S, Zhang Y, et al. Chronic infusion of norepinephrine into the VMH of nomml rats induces the obese glucose-intolerant state[J]. AmJ Physiol Regul Inte- gr Comp Physiol, 2000, 278(2) :R435.
  • 9Cincotta All, Meier AH, Cincotta M Jr. Bromocriptine im- proves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of dia- betes[J]. Expert Opin Investig Drugs, 1999, 8(10) : 1683.
  • 10Loew DM. Effects on the central nervous system//[ M ]. Berde H, Schild H. Ergot alkaloids and related compounds. New York: Springer- Verlag, 1978:421.

同被引文献67

  • 1刘纪宁.溴隐亭的临床应用[J].实用内科杂志,1989,9(11):613-615. 被引量：3
  • 2冯文忠,尹维珍,张桂仙,唐丽丽,李红.溴隐亭治疗肢端肥大症继发糖尿病与糖耐量异常报告[J].云南医药,1994,15(3):170-173. 被引量：2
  • 3项坤三.溴隐亭对成年型糖尿病的作用[J].国外医学:内分泌学分册,1981,3:162-163.
  • 4Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes[J]. Diabetes Care, 2000, 23(8): 1154.
  • 5Kerr JL, Timpe EM, Petkewicz KA. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus[J]. Ann Pharmacother, 2010, 44(11): 1777-1785.
  • 6Gaziano JM, Cincotta AH, Vinik A, et al. Effect of bromocripfine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects[J]. JAHA, 2012, 1(5): e002279.
  • 7Cineotta AH, Meier AH, Cineotta JrM. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes[J]. Expert Opin Investig Drugs, 1999, 8(10): 1683-1707.
  • 8Mikhail N. Quick-release bromocriptine for treatment of type 2 diabetes[J]. Curr Drug Deliv, 2011, 8(5): 511-516.
  • 9Cincotta AH, Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters(Mesocricetus auratus)[J]. Metabolism, 1995, 44(10): 1349-1355.
  • 10Defronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes[J]. Diabetes Care, 2011, 34(6): 789-794.

引证文献5

二级引证文献16

实用临床医药杂志
2011年 第13期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部